Akeso’s cadonilimab (bi-specific PD-1/CTLA-4) included in 2022 CSCO guidelines as primary recommendation for cervical cancer immunotherapy
HONG KONG, October 16, 2022 /PRNewswire/ — The Chinese Society of Clinical Oncology (CSCO), an authoritative Chinese oncology institution, recently released the 2022 CSCO Guidelines on Diagnosis and Treatment of Cervical Cancer. Akeo’s 开坦尼® (cadonilimab injection), a bi-specific PD-1/CTLA-4 antibody independently developed by the Company, has been included in the guidelines as a recommended second-line immunotherapy for recurrent or metastatic diseases. cervical cancer (R/M CC).
As the world’s first approved dual immune checkpoint bi-specific antibody, Cadoniliab is the first immuno-oncology drug approved for the advanced treatment of cervical cancer in China. It was granted marketing clearance by the National Medical Products Administration (NMPA) in late June 2022, addressing unmet market demand for immunotherapy for cervical cancer. Cadonilimab was included in the guidelines for the treatment of cervical cancer as the main recommendation of the CSCO only 4 months after its approval, which would allow clinicians in China to obtain a deeper understanding and more further study of the clinical efficacy of cadonilimab, it will further help Cadoniliab to respond more quickly and broadly to the needs of patients by improving their survival benefit.
China has the second largest population of cervical cancer patients in the world, with 110,000 new cases in 2020. Akeso is currently conducting a phase III trial combining cadonilimab and platinum-based chemotherapy +/ – bevacizumab in the first-line treatment of R/M CC and completed patient enrollment. In addition, a registration/Phase III trial of cadonilimab plus concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC) is also ongoing.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/akesos-cadonilimab-pd-1ctla-4-bi-specific-included-in-the-2022-csco-guidelines-as-the-top-recommendation-for- cervical-cancer-immunotherapy-301650315.html